- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04192669
Heart Rate Variability as a Clinical Marker in a Population of Anxio-depressive Patients
Study of Heart Rate Variability as a Clinical Marker in a Population of Anxio-depressive Patients
The heart rate (HR) is regulated by the autonomic nervous system (ANS) and results from a balance between the sympathetic nervous system (SNS) that accelerates the heart rate and the parasympathetic nervous system that slows the HR via the vagus nerve.
Low HRV is linked to poor emotional and cognitive regulation. Values for HRV are generally lower in depressed patients.
The aim of this study is to determine how HRV could be a clinical marker that can be used in routine psychiatry practice in patients with anxio-depressive disorders, to determine the severity of symptoms and the degree of response to treatment.
Study Overview
Status
Conditions
Intervention / Treatment
Study Type
Enrollment (Actual)
Contacts and Locations
Study Locations
-
-
-
Bruxelles, Belgium
- CHU Brugmann
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Sampling Method
Study Population
Description
Inclusion Criteria:
- Patients of the CHU Brugmann Hospital with an anxious or depressive disorder
Exclusion Criteria:
- None
Study Plan
How is the study designed?
Design Details
Cohorts and Interventions
Group / Cohort |
Intervention / Treatment |
---|---|
Anxio-depressive patients
Patients with a depressive or anxious disorder going to the Psychiatry Department of the CHU Brugmann Hospital.
|
The heart rate will be recorded and calculated by a heart rate monitor (Polar H10, Finland) located on the chest.
The recording is done over a period of 5 minutes, the patient being in a sitting position, without any particular stimulus, in a quiet room.
The recording is transferred via the HRV Logger application.
Any ectopic beats and artifacts are automatically identified and replaced by values interpolated by the investigator, if necessary.
The Kubios HRV Premium Software is used for all calculations.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Beck depression inventory (BDI)
Time Frame: Baseline (day of inclusion of the patient in the study).
|
Multiple choice (4 choices) questionnaire with 21 items.
The end score can vary between 0 and 63.
Score interpretation: 1-10: These ups and downs are considered normal.
11-16 Mild mood disturbance.
17-20 Borderline clinical depression.
21-30 Moderate depression.
31-40 : Severe depression.
Over 40 :Extreme depression.
|
Baseline (day of inclusion of the patient in the study).
|
Beck depression inventory (BDI)
Time Frame: Measured only once at one visit taking place minimum 3 months and maximum 6 months after baseline
|
Multiple choice (4 choices) questionnaire with 21 items.
The end score can vary between 0 and 63.
Score interpretation: 1-10: These ups and downs are considered normal.
11-16 Mild mood disturbance.
17-20 Borderline clinical depression.
21-30 Moderate depression.
31-40 : Severe depression.
Over 40 :Extreme depression.
|
Measured only once at one visit taking place minimum 3 months and maximum 6 months after baseline
|
State trait Anxiety inventory (STAI)
Time Frame: Baseline (day of inclusion of the patient in the study).
|
The State-Trait Anxiety Inventory (STAI) is a psychological inventory based on a 4-point Likert scale and consists of 40 questions on a self-report basis.
Scores range from 20 to 80, with higher scores correlating with greater anxiety.
|
Baseline (day of inclusion of the patient in the study).
|
State trait Anxiety inventory (STAI)
Time Frame: Measured only once at one visit taking place minimum 3 months and maximum 6 months after baseline
|
The State-Trait Anxiety Inventory (STAI) is a psychological inventory based on a 4-point Likert scale and consists of 40 questions on a self-report basis.
Scores range from 20 to 80, with higher scores correlating with greater anxiety.
|
Measured only once at one visit taking place minimum 3 months and maximum 6 months after baseline
|
Maslach Burnout inventory (MBI)
Time Frame: Baseline (day of inclusion of the patient in the study).
|
The Maslach Burnout Inventory (MBI) is an introspective psychological inventory consisting of 22 items pertaining to occupational burnout.
All MBI items are scored using a 7 level frequency scale from "never" to "daily."
Initial development had 3 components: emotional exhaustion (9 items), depersonalization (5 items) and personal achievement (8 items).
Each scale measures its own unique dimension of burnout.
Scales should not be combined to form a single burnout scale.
|
Baseline (day of inclusion of the patient in the study).
|
Maslach Burnout inventory (MBI)
Time Frame: Measured only once at one visit taking place minimum 3 months and maximum 6 months after baseline
|
The Maslach Burnout Inventory (MBI) is an introspective psychological inventory consisting of 22 items pertaining to occupational burnout.
All MBI items are scored using a 7 level frequency scale from "never" to "daily."
Initial development had 3 components: emotional exhaustion (9 items), depersonalization (5 items) and personal achievement (8 items).
Each scale measures its own unique dimension of burnout.
Scales should not be combined to form a single burnout scale.
|
Measured only once at one visit taking place minimum 3 months and maximum 6 months after baseline
|
Root mean square of successive differences (RMSSD)
Time Frame: Baseline (day of inclusion of the patient in the study).
|
The Root Mean Square of the Successive Differences (RMSSD) is one of a few time-domain tools used to assess heart rate variability, the successive differences being neighboring RR intervals.
It reflects the activity of the parasympathetic nervous system.
|
Baseline (day of inclusion of the patient in the study).
|
Root mean square of successive differences (RMSSD)
Time Frame: Measured only once at one visit taking place minimum 3 months and maximum 6 months after baseline
|
The Root Mean Square of the Successive Differences (RMSSD) is one of a few time-domain tools used to assess heart rate variability, the successive differences being neighboring RR intervals.
It reflects the activity of the parasympathetic nervous system.
|
Measured only once at one visit taking place minimum 3 months and maximum 6 months after baseline
|
High frequency percentage in the spectral analysis of the heart RR interval
Time Frame: Baseline (day of inclusion of the patient in the study).
|
Spectral analysis of the RR interval is an indirect, noninvasive measurement tool of heart rate variability.
High-frequency RR signals (0.15 to 0.4 Hz) reflect a parasympathetic activity and thus an influence of the vagal nerve on the heart.
A high frequency heart variability is associated with a better perception of emotions and with pro-social behaviors.
|
Baseline (day of inclusion of the patient in the study).
|
High frequency percentage in the spectral analysis of the heart RR interval
Time Frame: Measured only once at one visit taking place minimum 3 months and maximum 6 months after baseline
|
Spectral analysis of the RR interval is an indirect, noninvasive measurement tool of heart rate variability.
High-frequency RR signals (0.15 to 0.4 Hz) reflect a parasympathetic activity and thus an influence of the vagal nerve on the heart.
A high frequency heart variability is associated with a better perception of emotions and with pro-social behaviors.
|
Measured only once at one visit taking place minimum 3 months and maximum 6 months after baseline
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Toronto Alexithymia scale (TAS 20)
Time Frame: Baseline (day of inclusion of the patient in the study).
|
The TAS is a 20-item instrument that is one of the most commonly used measures of alexithymia.
Alexithymia refers to people who have trouble identifying and describing emotions and who tend to minimise emotional experience and focus attention externally.
The TAS-20 uses cutoff scoring: equal to or less than 51 = non-alexithymia, equal to or greater than 61 = alexithymia.
Scores of 52 to 60 = possible alexithymia.
|
Baseline (day of inclusion of the patient in the study).
|
Toronto Alexithymia scale (TAS 20)
Time Frame: Measured only once at one visit taking place minimum 3 months and maximum 6 months after baseline
|
The TAS is a 20-item instrument that is one of the most commonly used measures of alexithymia.
Alexithymia refers to people who have trouble identifying and describing emotions and who tend to minimise emotional experience and focus attention externally.
The TAS-20 uses cutoff scoring: equal to or less than 51 = non-alexithymia, equal to or greater than 61 = alexithymia.
Scores of 52 to 60 = possible alexithymia.
|
Measured only once at one visit taking place minimum 3 months and maximum 6 months after baseline
|
Difficulties in Emotion Regulation Scale (DERS-18)
Time Frame: Baseline (day of inclusion of the patient in the study).
|
The Difficulties in Emotion Regulation Scale is a self-report measure that evaluates individuals' levels of difficulties in regulating emotions.Higher scores indicate more difficulty in emotion regulation.
|
Baseline (day of inclusion of the patient in the study).
|
Difficulties in Emotion Regulation Scale (DERS-18)
Time Frame: Measured only once at one visit taking place minimum 3 months and maximum 6 months after baseline
|
The Difficulties in Emotion Regulation Scale is a self-report measure that evaluates individuals' levels of difficulties in regulating emotions.Higher scores indicate more difficulty in emotion regulation.
|
Measured only once at one visit taking place minimum 3 months and maximum 6 months after baseline
|
Collaborators and Investigators
Sponsor
Investigators
- Principal Investigator: Pierre Cole, MD, CHU Brugmann
Study record dates
Study Major Dates
Study Start (ACTUAL)
Primary Completion (ACTUAL)
Study Completion (ACTUAL)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (ACTUAL)
Study Record Updates
Last Update Posted (ACTUAL)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- CHUB-PSY-BRUHRV
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Anxio Depressive Disorder
-
Shalvata Mental Health CenterUnknownMAjor Depressive DisorderIsrael
-
York UniversityCentre for Addiction and Mental HealthSuspendedDisorder, Major DepressiveCanada
-
Wyeth is now a wholly owned subsidiary of PfizerCompletedDepressive Disorder, Major Depressive DisorderUnited States
-
Seasons Biotechnology (Taizhou) Co., Ltd.CompletedMajor Depressive Disorder (MDDIndia
-
Gangnam Severance HospitalCompletedMajor Depressive Disorder(MDD)Korea, Republic of
-
University College, LondonCompletedUnipolar Major Depressive DisorderUnited Kingdom
-
Fundació Institut de Recerca de l'Hospital de la...Fondo de Investigacion SanitariaUnknown
-
Samsung Medical CenterUnknownMajor Depressive Disorder, Anxiety DisorderKorea, Republic of
-
Seasons Biotechnology (Taizhou) Co., Ltd.CompletedMajor Depressive Disorder (MDD)India
-
Repurposed Therapeutics, Inc.Unknown
Clinical Trials on Heart rate monitoring
-
KK Women's and Children's HospitalRenew GroupCompletedHeart Rate | Respiratory Rate | Vital SignSingapore
-
Washington University School of MedicineTerminatedLabor, Obstetric | Fetal MonitoringUnited States
-
Regional Hospital HolstebroCompletedHealthy | White Coat Hypertension | Essential HypertensionDenmark
-
Nordlandssykehuset HFUniversity of TromsoCompletedSleep | Cluster HeadacheNorway
-
Intermountain Health Care, Inc.GE HealthcareCompleted
-
Seoul National University Bundang HospitalActive, not recruitingGraves' Disease in Remission (Disorder)Korea, Republic of
-
Czech Technical University in PragueEnrolling by invitationHypertension | Blood PressureCzechia
-
University of Turin, ItalyPolitecnico di MilanoCompletedDiagnoses Disease | Vagus Nerve DiseasesItaly
-
University of Campania "Luigi Vanvitelli"CompletedFetal Conditions | Fetal Movement DisorderItaly